ClinActiv Holdings to Acquire Crescita Therapeutics

Cresco Labs to Acquire Columbia Care in Definitive Transaction

July 8, 2022

Healthcare Services

Cresco Labs entered into a definitive arrangement agreement to acquire all of the issued and outstanding shares of Columbia Care. Shareholders of Columbia Care approved the plan of arrangement at a special meeting, and the transaction is expected to close in the fourth quarter of 2022 subject to customary conditions and approvals.

Sorrento Therapeutics Acquires ACEA Therapeutics

June 1, 2021

Biotechnology

Sorrento Therapeutics completed the acquisition of ACEA Therapeutics, making ACEA a wholly owned subsidiary and issuing Sorrento common stock plus contingent milestone and royalty payments. The deal adds multiple clinical- and preclinical-stage new chemical entities (including abivertinib) to Sorrento's oncology and immunotherapy pipeline and expands its development and manufacturing footprint in China and North America.

Cresco Labs Acquires Cultivate in Massachusetts

September 3, 2021

Retail

Cresco Labs has closed its acquisition of Cultivate, a vertically integrated Massachusetts cannabis operator with three dispensaries and approximately 42,000 square feet of active cultivation canopy. The deal increases Cresco's in-state cultivation to ~64,000 square feet and expands its retail footprint in Massachusetts as part of a strategy to deepen presence in large, attractive state markets.

Innoviva Acquires Entasis Therapeutics

May 23, 2022

Biotechnology

Innoviva agreed to acquire the remaining shares of Entasis Therapeutics it did not already own for $2.20 per share in cash, valuing Entasis equity at about $113 million on a fully diluted basis. Innoviva completed the acquisition in July 2022, making Entasis a wholly owned subsidiary.

Pharmacosmos Acquires G1 Therapeutics

August 7, 2024

Biotechnology

Pharmacosmos A/S, through its U.S. affiliate Pharmacosmos Therapeutics Inc., agreed to acquire all outstanding shares of G1 Therapeutics, Inc. for $7.15 per share in cash, implying an approximate equity value of $405 million. The deal brings G1's FDA-approved oncology product COSELA into Pharmacosmos' commercial portfolio to accelerate patient access and expand Pharmacosmos' presence in oncology and supportive care.

Cresco Labs Acquires Laurel Harvest Labs

December 10, 2021

Consumer Products

Cresco Labs has completed the acquisition of Pennsylvania clinical registrant Laurel Harvest Labs, adding ~52,000 sq. ft. of indoor cultivation/processing capacity, an operational dispensary in Montgomeryville and a second dispensary under construction in Scranton. The deal expands Cresco’s retail and cultivation footprint in Pennsylvania to strengthen its wholesale market position and support clinical research partnerships.